Switch to metronomic therapy could offer new treatment option for patients with advanced kidney cancer

February 15, 2010

A new multi-targeted "chemo-switch" drug regimen shows promising anti-tumour activity with manageable side effects in patients with metastatic renal-cell carcinoma (RCC), a disease with few treatment options. Combining maximum tolerated dose (MTD) chemotherapy (gemcitabine) with metronomic chemotherapy (frequent low-dose chemotherapy with capecitabine) plus sorafenib (a targeted drug), results in greater progression-free survival (PFS) and tumour response than previously reported with sorafenib alone or with chemotherapy, and might provide a new first-line treatment option for patients with advanced kidney cancer, concludes an Article published Online First in The Lancet Oncology.

RCC is the most common form of kidney cancer, causing over 102,000 deaths worldwide each year. But treatment options are limited and survival is poor, with responses to chemotherapy, hormonal and biological therapy, and standard treatment with targeted drugs remaining modest.

However, recent preclinical studies have suggested that combining treatment options could improve response to treatment and survival. Combined treatment entails initial treatment at the MTD of one chemotherapy drug (to kill all rapidly growing cells), followed by maintenance with a metronomic dose of a second chemotherapy drug (giving patients lower doses more frequently to prevent the cancer from growing by inhibiting the development of new blood vessels) plus a targeted inhibitor of vascular endothelial growth factor (VEGF) and platelet-derived growth factor receptor (PDGFR) to increase anti-tumour activity.

To investigate whether this multi-targeted "chemo-switch" strategy might improve outcomes in patients with metastatic RCC, Joaquim Bellmunt from University Hospital del Mar, Barcelona, Spain, and colleagues from the Spanish Oncology Genitourinary Group (SOGUG) did a phase 2 study involving 44 patients from eight centres across Spain. 40 patients received six cycles of treatment consisting of MTD gemcitabine (days 1 and 8) with metronomic capecitabine twice a day, and VEGFR and PDGFR inhibitor sorafenib twice a day (days 1󈞁), followed by sorafenib monotherapy.

Findings showed that median PFS was 11.1 months, compared with previous results with gemcitabine and capecitabine of 5𔃆 months, and less than 7 months with sorafenib alone. Additionally, a partial response was reported in 50% of patients, compared with 16% of patients in previous studies with gemcitabine and capecitabine, and less than 5% of patients with sorafenib alone. Stable disease was achieved in 17 (42.5%) patients.

All patients reported at least one adverse event during the study, with over half reporting a grade 3 event. However, these events were manageable in most patients, with fatigue and asthenia, hand-foot skin reactions, and neutropenia the only grade 3 adverse events reported in more than 10% of patients.

The authors say: "The combination of sorafenib with MTD gemcitabine and metronomic capecitabine resulted in a clinical benefit rate of over 90%, with an acceptable level of toxicity."

They go on: "Further studies are therefore needed to confirm the effect on a broader patient population, to clearly identify the optimal balance between clinically meaningful efficacy and manageable toxicity, and to attempt to define prognostic factors for identifying those patients in whom the treatment is most likely to be effective and least likely to be toxic."
Dr Joaquim Bellmunt, University Hospital del Mar-IMIM, Barcelona, Spain. T) +34 93 248 3137 E) jbellmunt@imas.imim.es

For full Article see: http://press.thelancet.com/tlobellmunt.pdf


Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.